Celgene touts mid-stage psoriasis results

Researchers for Celgene are changing the dosing and duration of their tests of an experimental psoriasis drug after seeing a significant reduction in severity and symptoms in a mid-stage study. A 260-patient study of CC-10004 demonstrated that 24.4 percent of patients treated with 20 milligrams of CC-10004 every 12 hours had a 75 percent or greater reduction in psoriasis severity and symptoms. A placebo registered a 10.3 percent reduction. Patients can now get doses of 30 mgs for up to six months and Celgene will expand the trial to include related conditions. No serious side effects were reported.

- see this release
- check out the AFX report

Suggested Articles

After Mallinckrodt's terlipressin beat placebo at reversing kidney failure, an FDA panel will discuss the phase 3 trial's surrogate endpoint.

Operation Warp Speed is living up to its name as AstraZeneca is teaming up with IQVIA to boost its R&D for its pandemic shot.

The deal, which is worth up to $160 million per molecule in milestones, comes as Junshi tries to pull off a $684 million IPO.